DiaMedica Therapeutics IncNASDAQ:DMAC
- LAST PRICE2.4200
- TODAY'S CHANGE (%)-0.0700 (-2.8112%)
- Bid / Lots2.4200/ 1
- Ask / Lots2.4800/ 1
- Open / Previous Close2.4900 / 2.4900
- Day Range
- 52 Week Range
- Volume15,780
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DMAC |
|---|---|---|
| 09:32 ET | 1119 | 2.49 |
| 09:34 ET | 180 | 2.5412 |
| 10:19 ET | 100 | 2.455 |
| 11:04 ET | 2200 | 2.46 |
| 11:33 ET | 100 | 2.46 |
| 11:49 ET | 1000 | 2.4501 |
| 12:09 ET | 1000 | 2.4497 |
| 12:41 ET | 130 | 2.4402 |
| 12:52 ET | 9016 | 2.42 |
| 12:56 ET | 100 | 2.42 |
| 01:08 ET | 100 | 2.42 |
| 02:09 ET | 100 | 2.42 |
Apr 17, 2024
Mar 21, 2024
DJ Diamedica Therapeutics Is Maintained at Buy by Craig-Hallum, from 2:41PM ET on Thursday Mar 21, 2024 by Dow Jones
2:41PM ET on Thursday Mar 21, 2024 by Dow JonesDJ Diamedica Therapeutics Price Target Cut to $6.00/Share From $7.00 by Oppenheimer, from 8:53AM ET on Thursday Mar 21, 2024 by Dow Jones
8:53AM ET on Thursday Mar 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DiaMedica Therapeutics Inc | 94.5M | -3.9x | --- |
Allakos Inc | 93.1M | -0.5x | --- |
IO Biotech Inc | 96.8M | -0.7x | --- |
Anixa Biosciences Inc | 98.9M | -9.2x | --- |
Vigil Neuroscience Inc | 101.4M | -1.3x | --- |
Sellas Life Sciences Group Inc | 85.5M | -1.1x | --- |
Company Information
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Contact Information
- Headquarters
- 301 CARLSON PARKWAY, SUITE 210MINNEAPOLIS, MN, United States 55305
- Phone
- 763-496-5454
- Fax
- 763-710-4456
Executives
- Independent Chairman of the Board
- Richard Pilnik
- President, Chief Executive Officer, Director
- Rick Pauls
- Chief Financial Officer, Company Secretary
- Scott Kellen
- Senior Vice President - Clinical Development Operations
- Julie Daves
- Chief Technology Officer
- Ambarish Shah
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $94.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-0.62 |
Book Value | $1.35 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
